- Home
- BNC vs AARD Comparison
BNC vs AARD Comparison
Compare BNC & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNC | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 281.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BNC | AARD |
|---|---|---|
| Price | $2.84 | $3.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 230.7K | ★ 472.0K |
| Earning Date | 03-16-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,107.17 |
| P/E Ratio | $0.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $3.41 |
| 52 Week High | $31.62 | $17.94 |
Technical Indicators
Market Signals| Indicator | BNC | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 19.40 |
| Support Level | N/A | N/A |
| Resistance Level | $4.14 | $6.19 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 1.16 | 6.74 |
Price Performance
Historical ComparisonAbout BNC CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.